Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with advanced or locally advanced colorectal cancer that has a specific genetic feature known as dMMR or MSI-H
- People who are expected to receive, or are already receiving, a type of cancer treatment called immune checkpoint inhibitor therapy
- People who are in reasonably good general health (rated 0 or 1 on a standard medical scale) and have a life expectancy of at least 12 weeks
Who may not be able to join:
- People who have another cancer that has not yet been treated or cured
- People who have one or more serious ongoing illnesses that, in the opinion of the trial doctor, would make it difficult to complete the study
- People who have an autoimmune disease that makes a specific type of cancer treatment (PD-1 monoclonal antibody therapy) unsuitable for them (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaoyan Zhou, PhD, Fudan University
Phone: +86 13524324387
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Correlation of ctDNA changes with pCR rate and the duration of cCR
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.